Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

Abstract: Devices, systems and methods for cleaning a surface of as elongated instrument held within a cavity. In particular embodiments of the device, a longitudinal wire member extends along an elongated instrument (e.g. a laparoscope) and a rotatable transverse member removes matter from a surface of the instrument (e.g. a lens).

Abstract: A method of electrochemical sensing includes providing an electrochemical sensor comprising a glassy carbon substrate and gold nanoparticles located on a surface of the glassy carbon substrate; and sensing electrochemically a compound selected from the group consisting of polyfluoroalkyl compounds or perfluoroalkyl compounds using the electrochemical sensor. PFOA quantification was performed by Square Wave Adsorptive Cathodic Stripping Voltammetry (SW-AdCSV) in test solutions with a 100-5,000 ppt concentration. The concentration has a linear relationship with the stripping current within this range. Analysis of tap and groundwater samples performed by additions method demonstrated precision and accuracy above 95%. These electrodes show stability throughout 200 cycles, and reproducibility across similarly prepared but different electrodes above 97.5%.

Abstract: System and methods for producing synthesis gas are provided. The system includes a reactor and a steam generation system designed to provide precise control of the rate of steam generation to mix steam with fuel gas to produce humidified fuel gas, which is then fed into a combustion chamber of the reactor. The molar ratio of hydrogen to carbon monoxide in the synthesis gas output from the reactor may be accurately controlled by adjusting the humidity of the fuel gas input into the combustion chamber.

Abstract: In some aspects, the present disclosure provides a nanoparticle composition comprising tRNA and an aminolipid delivery compound. The aminolipid delivery compound may be a dendrimer, dendron, or dendritic lipid, a polymer such as a polyamide or polyester, or a lipid with one or more hydrophobic components. In some embodiments, these compositions may be administered to a patient to treat a genetic disease or disorder such as cystic fibrosis, Duchene muscular dystrophy, or cancer.

Abstract: A novel framework to transform a T-cell receptor (TCR) repertoire sample into a fixed-length vector. Short peptide sequences with different lengths in each TCR may be encoded into a numeric vector with fixed dimensions. A large amount of existing TCRs from healthy individuals may be pooled to generate a distribution of the encoding vector in a high-dimensional Euclidean space. Unsupervised clustering may be performed on the “points” in this space (each point is a TCR) to group them into antigen-specific clusters. The centroid of each cluster may be defined as a repertoire functional unit (“RFU”). For a new TCR repertoire sample, each TCR may be assigned to its most similar RFU group, and the RFU counts may be normalized by the number of sequences in the repertoire. The output data may be a fixed-length RFU vector, with each number representing the relative abundance of the given RFU in the repertoire.

Abstract: Embodiments can take brain activity measurement and decode into continuous language. Embodiment can use non-invasive brain recordings, such as functional magnetic resonance imaging (fMRI) and functional near-infrared spectroscopy (fNIRS) to detect changes in blood oxygen level that are coupled to neural activity. These brain recordings can be used by a language reconstruction model that involves a neural language model to predict a next word in a sequence and an encoding model to decode the recordings into continuous language, or sequences of words.

Abstract: Described herein are methods and systems for identifying and/or treating subjects having cancer who are more likely to respond to treatment with an inhibitor of the transcription factor HIF-2?.

Abstract: The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.

Abstract: Methods for treating, reducing, ameliorating or inhibiting symptoms idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia, comprising administering to a subject in need of an effective amount of a) multiple EGF-like-domains-9 (MEGF9) or a biologically active fragment thereof; b) uncoordinated receptor 5A (UNC5A) or a biologically active fragment thereof; c) dolichyl-phosphate beta-glucosyltransferase (ALG5) or a biologically active fragment thereof; d) a combination of two or three of a)-c); e) an antibody specifically binding to a); f) an antibody specifically binding to b); g) an antibody specifically binding to c); h) a combination of two or three of e)-g); or i) a combination of at least one of a)-c) and at least one of e)-g). Pharmaceutical compositions and processes for making and using the compositions are also disclosed.

Abstract: An imaging system configured to transform a lateral scan motion into axial refocusing, thus enabling aberration free remote focusing. In one embodiment, the imaging system provides aberration free remote focusing by causing a beam of light to be scanned over a stationary mirror having a variable height in the scan direction, thereby causing the beam of light to be defocused in an axial direction in the return direction (e.g., the direction of propagation for the reflected beam of light). By configuring the back-reflected light resulting from the lateral scan component as described herein, a pure axial scan motion may be obtained at the rate of the employed (lateral) scanning technology (e.g., a GSM). This capability allows the imaging system of the present inventive concept to leverage rapid lateral scan technologies to produce rapid axial displacement of the axial focus of the beam of light.

Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

Abstract: The invention relates generally to an allele on human chromosome 9 associated with increased risk for coronary heart disease and the use or detection of such an allele in determining whether a human has an increased risk for coronary heart disease. In one aspect, the invention relates to methods for detecting a predisposition or propensity or susceptibility for coronary heart disease in a human, comprising detecting the presence of an allele on human chromosome 9 that is associated with an increased risk for coronary heart disease in a human. Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has an RA-CHR9 allele, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP). The invention also relates to kits for detecting the presence of an allele on chromosome 9 associated with an increased risk for coronary heart disease.

Abstract: In one aspect, a neuromodulation device is described herein. In some embodiments, a neuromodulation device comprises a chamber operable to receive a nerve, at least one electrode disposed in the chamber, and a channel defined by two walls. In some embodiments, the channel of the device is in fluid communication with an interior of the chamber and an external surface of the device. In another aspect, methods of neuromodulation are described herein. In some embodiments, methods described herein can use one or more neuromodulation devices described herein.

Abstract: Aspects of the present disclosure relate to methods and compositions for altering a tumor microbiome. Certain aspects are directed to methods for manipulating a tumor microenvironment for promotion of a tumor restraining microbiome and treatment of cancer. Particular aspects include methods for treating cancer comprising administration of an immunotherapy and an agent capable of disrupting an interaction between ?3?1 integrin and ?1 homotrimeric type I collagen.

Abstract: Aspects of self-powered weigh-in-motion systems and methods that utilize piezoelectric components for sensing load as well as powering data acquisition and analysis components. In one example, the weigh-in-motion system includes a number of piezoelectric stacks, each stack including a number of piezoelectric elements. Each stack includes one or more top or upper piezoelectric element that provides vehicle sensing data. Each stack also includes a set of piezoelectric elements used for energy harvesting. The sensing piezoelectric elements are connected to a data input of a microcontroller for vehicle classification, while the energy harvesting piezoelectric elements are connected to a power input of the microcontroller.

Abstract: A method includes obtaining a first imaging scan and a second imaging scan of a single subject brain. The first imaging scan is converted to a first dataset, and the second imaging scan is converted to a second dataset. A sequence-adaptive multimodal segmentation algorithm is applied to the first dataset and the second dataset. The sequence-adaptive multimodal segmentation algorithm performs automatic intensity-based tissue classification to generate a first labelled dataset and a second labeled dataset. The first labeled dataset and the second labeled dataset are automatically co-registered to each other to generate a transformation matrix based on the first labeled dataset and the second labeled dataset. The transformation matrix is applied to align the first dataset and the second dataset.

Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.

Abstract: Methods of treating or preventing a respiratory disease or condition in a subject in need thereof, inflating the lungs of a subject in need thereof, and reducing the positive-end expiratory pressure (PEEP) needed for mechanical ventilation, the methods comprising administering an effective amount of a composition comprising one or more perfluorocarbons to the subject.

Abstract: A method and system for detecting and analyzing internet traffic from Internet of Things (IoT) devices is presented. A network telescope is employed to collect unsolicited data packets. The data packets are analyzed to determine whether they arise from a misconfigured device or from a malicious device (darknet sanitization) or from some other source. Traffic from misconfigured devices is filtered out. The data packets from malicious devices are analyzed and a classification model is trained to classify the data packets into originating from an IoT or from a non-IoT device. The classifier is then validated on a separate set of data. The data packets originating from malicious IoT devices are further analyzed by such techniques a clustering (e.g. agglomerative hierarchical clustering), geo-location analysis, methods of attack, and coordination of attacks.